Pankit Vachhani, MD

Articles

Future of MF

February 16th 2024

Experts discuss how treatments, either monotherapy or combination, may impact the treatment landscape for MF and how they might choose among the new agents.

Combination Therapies for MF Management

February 9th 2024

Panel experts comment on the role of combination therapies in MF and debate if these therapies will be the new standard of care.

Future of PV: Unmet Needs

February 9th 2024

Faculty offer insights into the future of PV management as well as unmet needs.

Monitoring Patients on Myelofibrosis Treatment

February 2nd 2024

Faculty discuss the best strategies to monitor patients who are receiving treatment of MF as well as commenting on when it might be appropriate to switch therapies.

Treating Patients with Myelofibrosis and Anemia

February 2nd 2024

Expert oncologists provide insights into how they might manage patients who present with anemia and myelofibrosis in their practice.

Myelofibrosis: FDA Approved Treatment Options and Updates from ASH 2023

January 26th 2024

Overview of the current FDA approved treatment options for the management of myelofibrosis as well as reviewing recent updates from ASH 2023 on the SIMPLIFY and PERSIST trials.

Role of Transplant in Myelofibrosis

January 26th 2024

Panel experts comment on the role of transplant in patients with myelofibrosis.

MAJIC-PV: Clinical Implications in PV

January 19th 2024

Experts discuss the clinical implications of the MAJIC-PV trial.

Polycythemia Vera: Choosing the Right Treatment

January 19th 2024

Panel experts talk about when to use cytoreductive therapy and which factors influence their treatment selection as well as reviewing how patients with PV are monitored.

Polycythemia Vera: Treatment Goals and Options

January 12th 2024

Faculty discuss the treatment goals for patients diagnosed with polycythemia vera and review treatment options for managing PV.

REVEAL Study: Clinical Implications

January 12th 2024

Expert oncologists discuss the REVEAL study and provide their thoughts on these data and the impact in clinical practice.

Polycythemia Vera: Assessing Risk and Genetic Testing

January 12th 2024

Experts discuss the optimal strategy for NGS testing, which alterations to test for and how to assess for risk when diagnosing and managing patients with polycythemia vera (PV).

Diagnosing Polycythemia Vera (PV)

December 19th 2023

Experts explain how polycythemia vera is diagnosed and the typical symptoms a patient may present with.

KIT Inhibitors Lead to Shift in Treatment of Systemic Mastocytosis

September 26th 2023

The hematologic neoplasm systemic mastocytosis is marked by the clonal proliferation of mast cells in the skin, bone marrow, gastrointestinal tract, spleen, and/or liver, caused by an activating KIT mutation in the KIT gene.

Looking Ahead in Treating Myeloproliferative Neoplasms

April 26th 2023

Shared closing thoughts on the future treatment landscape for myeloproliferative neoplasms, including future and emerging areas of research and remaining areas of unmet need.

Potential Combination Therapy Approaches with Ruxolitinib in Myelofibrosis

April 26th 2023

A review of recent trial data evaluating combination therapy approaches with ruxolitinib in myelofibrosis, including the rationale and potential clinical benefits associated with the use of these emerging strategies.

Novel Therapies Under Investigation for Myelofibrosis

April 19th 2023

Focused discussion on emerging trial data surrounding novel, investigational therapies for myelofibrosis.

Treatment Sequencing Approaches for Myelofibrosis

April 19th 2023

Expert perspectives on treatment sequencing strategies with JAK inhibitors for myelofibrosis.

Monitoring Strategies in Myelofibrosis

April 12th 2023

Shared insights on monitoring strategies for myelofibrosis, including important considerations for patients receiving treatment with JAK inhibitors.

JAK Inhibitors in Myelofibrosis

April 12th 2023

Panel experts briefly review supporting data for the use of JAK inhibitors in myelofibrosis and discuss the impact of emerging data on the current treatment landscape.